Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more
Market Cap & Net Worth: Hemostemix Inc (HMTXF)
Hemostemix Inc (OTCQB:HMTXF) has a market capitalization of $13.23 Million ($13.23 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #28331 globally and #9454 in its home market, demonstrating a -4.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemostemix Inc's stock price $0.07 by its total outstanding shares 188488541 (188.49 Million).
Hemostemix Inc Market Cap History: 2025 to 2025
Hemostemix Inc's market capitalization history from 2025 to 2025. Data shows growth from $13.23 Million to $13.23 Million (0.00% CAGR).
Hemostemix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemostemix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HMTXF by Market Capitalization
Companies near Hemostemix Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Hemostemix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hemostemix Inc Historical Marketcap From 2025 to 2025
Between 2025 and today, Hemostemix Inc's market cap moved from $13.23 Million to $ 13.23 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $13.23 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hemostemix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.23 Million USD |
| MoneyControl | $13.23 Million USD |
| MarketWatch | $13.23 Million USD |
| marketcap.company | $13.23 Million USD |
| Reuters | $13.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.